Introduction
Johnson & Johnson (JNJ) has been one of the safest investments in the healthcare sector for many years. Its size, diversification, and dividend growth have long shielded investors from volatility in the market while still making them good returns. Johnson & Johnson, however, is focusing more resources on the pharmaceuticals sector which should provide even more impetus for growth. Although there is more risk involved in pharmaceuticals, Johnson & Johnson’s many advantages in the field will provide significant upside to investors in the coming years.
Fundamentals
| Company | Johnson & Johnson | Pfizer | Merck | Novartis |
| Market Cap | 354.71B | 202.507B | 174.89B | 196.11B |
| P/E | 22.1 | 24.8 | 34.6 | 30.6 |
| PEG | 3.5 | 2.3 | 3.4 | 4.2 |
| P/B | 4.9 | 3.5 | 4.4 | 2.8 |
| P/S | 5.0 | 4.0 | 4.4 | 4.1 |
| P/Cash Flow | 17.4 | 13.5 | 17.4 | 16.1 |
| Operating Margin | 29.1% | 26.4% | 18.5% | 16.1% |
| FCF Yield | 5.0% | 6.6% | 4.9% | 4.9% |
| FCF/Sales | 24.29% | 25.37% | 21.28% | 19.56% |
| Debt to Equity | 0.38 | 0.58 | 0.55 | 0.33 |
Johnson & Johnson’s fundamentals provide an interesting look at the company and show a few key attributes of the business. Its fundamentals do not indicate that the company is overvalued since it has the lowest P/E of its peers, and other numbers, such as PEG, P/B, P/S, and P/Cash Flow, are in line with those of the other companies. However, its market cap and debt-to-equity numbers are important to analyze. Johnson & Johnson is worth $150 billion than its nearest competitor which gives it more reach and more resources to not only grow and compete in improving market share and sales, but also to weather any difficulties that the industry could face. The debt-to-equity ratio is important because it indicates that Johnson & Johnson is using its own cash flow rather than outside financing to fund operations and acquisitions (such as the $30 billion acquisition of Actelion recently.

